Roche signs its new diabetes business manager in Spain to Isdin

Roche signs its new diabetes business manager in Spain to Isdin. The Swiss multinational has just appointed Josep Maria Vallmajó as the new manager of Roche Diabetes Care Spain, a company of the pharmaceutical group that operates independently, as confirmed by company sources. 

What has not transcended is the position held or will continue to be held by Lisa Huse, who has been responsible for Roche Diabetes Care Spain since 2017 and was previously Vice President of Marketing, Strategy, and Innovation at Roche Diagnostic. The sources consulted indicated that Huse will hold a regional position in the United States. 

Roche Diabetes Care Spain, founded in 2015, specializes in glucose and insulin infusion monitoring devices for the treatment of Accu-Chek diabetes, and in comprehensive management solutions supported by Emminens Healthcare Services’ digital platforms. It also integrates the IT Hub, a global IT development center, and the ICC, an international call center for personalized attention to patients, customers, and healthcare professionals.   

If you want to read more on the subject and to find the details of the arrangement, download for free our companion app. Born2Invest mobile app brings you the most important finance news in the world and the latest updates in the business world so you can stay informed.

Roche Diabetes Care Spain was founded in 2015 and specializes in glucose monitoring and insulin infusion devices for the treatment of diabetes

Under the Accu-Chek brand, Roche Diabetes Care provides comprehensive diabetes management solutions for controlling glucose levels and delivering insulin, as well as data management platforms relevant to the management of the disease by patients, healthcare professionals and managers. 

Vallmajó is an industrial engineer from the University of Girona and has a master’s degree in Business Consulting and Business Advice from the School of Industrial Organization (EOI). In the last three years, the manager has been part of the Isdin group. In Isdin, Vallmajó worked as head of medical sales and later as sales manager for the company specialized in dermatology. In addition, the manager has worked for the consulting firm PwC.  

The multinational company recorded sales of €41.09 million in the first nine months of 2020, a year-on-year decrease of 5%

Roche is one of the world’s leading pharmaceutical companies, with differentiated medicines in the areas of oncology, immunology, infectious diseases, ophthalmology and neurosciences. Roche is also a reference in in vitro diagnosis and histological diagnosis of cancer. The group has its headquarters in Basel (Switzerland) and is operationally present in more than one hundred countries. 

According to the latest available results, corresponding to September 2020, the multinational recorded sales of 43.98 million Swiss francs (€41,09 million) in the first nine months of 2020, a decrease of 5% compared to the same period last year. By business segment, the Pharmaceuticals Division posted a turnover of 34.32 million Swiss francs (€32.07 million) in the period, a fall of 6%. By contrast, the diagnostics division recorded growth of 2%, with revenues of 9.66 million francs (€9.03 million).

__

(Featured image by JoaquinAranoa via Pixabay)

DISCLAIMER: This article was written by a third party contributor and does not reflect the opinion of Born2Invest, its management, staff or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the Company may believe that its expectations are based on reasonable assumptions, the actual results that the Company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the Company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in PlantaDoce, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Born2Invest assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Born2Invest is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.